Kemwell Biopharma: Cipla announces JV with Kemwell Biopharma Manipal Education & Medical Group in US

The JV is for global development and commercialisation of innovative cell therapy products Cipla (EU), UK a wholly-owned subsidiary of Cipla, hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma (through its subsidiary Kemwell Biopharma UK) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the US. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products for major unmet medical needs in the US, Japan, and EU regions. Cipla (EU) will secure a 35.2 per cent stake in the joint venture company. By capitalising on Cipla's leadership in product development and commercialisation and aligning with Kemwell's expertise in biologics and Manipal's expertise in healthcare delivery, this strategic collaboration is aimed at expediting development, manufacturing, licensing, import and export of cutting-edge Cell therapy products to cater to patients globally. Umang Vohra, MD and Global CEO, Cipla, said, "The joint venture reinforces our concerted efforts to move up the innovation curve and pioneer transformative treatments in the areas of stem cell and CAR T-cell therapies, enabled by advances in biotech, mRNA and cell-engineering research, that can make a difference to patient ...